Table 3 Number of observed second primary cancers (Obs) following breast cancer, diagnosed between 1958 and 2000, standardised incidence ratios (SIRs), and 95% confidence interval (CI) for second primary malignancy according to family history of breast cancer
Family history of breast cancer | |||||||
|---|---|---|---|---|---|---|---|
Yes | No | ||||||
Second primary cancer site | Obs | SIR | 95% CI | Obs | SIR | 95% CI | Ratio |
Oesophagus | 7 | 3.76 | (1.49–7.07) | 58 | 1.69 | (1.29–2.16) | 2.22* |
Stomach | 27 | 2.65 | (1.74–3.74) | 296 | 1.41 | (1.26–1.58) | 1.88* |
Colorectum | 46 | 1.10 | (0.81–1.45) | 1010 | 1.18 | (1.11–1.25) | 0.93 |
Pancreas | 9 | 0.86 | (0.39–1.52) | 253 | 1.18 | (1.04–1.33) | 0.73 |
Lung | 16 | 0.91 | (0.52–1.41) | 483 | 1.45 | (1.32–1.58) | 0.63 |
Endometrium | 41 | 1.94 | (1.39–2.58) | 589 | 1.45 | (1.34–1.57) | 1.33 |
Ovary | 40 | 2.32 | (1.66–3.10) | 437 | 1.38 | (1.25–1.51) | 1.68* |
Kidney | 8 | 0.89 | (0.38–1.61) | 239 | 1.29 | (1.14–1.46) | 0.69 |
Melanoma | 18 | 1.67 | (1.00–2.53) | 231 | 1.28 | (1.12–1.45) | 1.31 |
Nervous system | 13 | 1.20 | (0.63–1.94) | 236 | 1.25 | (1.09–1.41) | 0.96 |
Thyroid | 5 | 1.51 | (0.48–3.12) | 104 | 1.78 | (1.46–2.14) | 0.85 |
Endocrine glands | 12 | 1.37 | (0.70–2.25) | 199 | 1.19 | (1.03–1.36) | 1.15 |
Connective tissue | 5 | 2.48 | (0.78–5.12) | 79 | 2.06 | (1.63–2.54) | 1.20 |
Non-Hodgkin's lymphoma | 23 | 2.41 | (1.52–3.49) | 231 | 1.13 | (0.99–1.28) | 2.13* |
Leukaemia | 19 | 2.25 | (1.35–3.38) | 218 | 1.29 | (1.13–1.47) | 1.74* |
All the above sites | 289 | 1.58 | (1.40–1.77) | 4663 | 1.31 | (1.27–1.35) | 1.21* |